Skip to Main Content
Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and refreshing, because that oh-so familiar routine of online calls, deadlines, and planning has predictably returned. But what can you do? The world, such as it is, keeps spinning. To cope, yes, we are in the Pharmalot cafeteria brewing cups of stimulation. Our choice today is vanilla macadamia nut. As always, we invite you to join us. Meanwhile, here is the latest line up of items of interest to help you start your own day. Hope all goes well and you conquer the world, or at least do something productive. In any event, keep in touch. …

A preliminary decision on Medicare coverage for the Biogen (BIIB) Alzheimer’s drug is due this week. And even though the battered company has since cut the price of its drug in half and the Food and Drug Administration narrowed recommended use, experts agree that state Medicaid programs may face a crisis, STAT explains. The scenario is raising hard questions about what some say is a need to examine whether these state programs should have more flexibility in setting coverage in order to avoid budgetary blowback. “Should states use scarce resources to pay for a drug, even if Medicare decides it isn’t reasonable and necessary for patients,” asks Rachel Sachs of Washington University Law School.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment